吉西他滨联合S-1新辅助化疗对胰腺癌营养状态及胰十二指肠切除术结局的影响
本研究比较了可切除胰腺导管腺癌患者直接行胰十二指肠切除术与接受吉西他滨联合S-1新辅助化疗后再手术的围术期营养状态和手术结局。
要点
- 吉西他滨联合S-1新辅助化疗未对术前营养状态造成不良影响。
核心结论
- 吉西他滨联合S-1新辅助化疗不损害可切除胰腺导管腺癌患者的术前营养状态,并提高胰十二指肠切除术的R0切除率和总生存。
主要发现
- 术前营养评估(血清白蛋白、CONUT评分、PNI)在初诊时和术前均无显著组间差异。
- 术后结局包括出血量、手术时间和并发症发生率无显著差异。
临床怎么用
- 可切除胰腺导管腺癌患者可考虑吉西他滨联合S-1新辅助化疗,以期提高R0切除率和改善生存,且不增加营养风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the advent of improved chemotherapy options, neoadjuvant chemotherapy has gained acceptance as a multidisciplinary treatment approach for localized pancreatic ductal adenocarcinoma. This study aimed to clarify whether neoadjuvant chemotherapy with gemcitabine and S-1 influences preoperative nutritional status and postoperative outcomes, particularly in patients undergoing highly invasive pancreatic resection. METHODS: Patients with resectable pancreatic ductal adenocarcinoma who underwent pancreaticoduodenectomy as upfront surgery or after neoadjuvant chemotherapy with gemcitabine and S-1 between January 2015 and December 2022 were assessed. In addition to perioperative surgical outcomes, preoperative nutritional status was evaluated using serum albumin, controlling nutritional status, and prognostic nutritional index. RESULTS: A total of 158 patients who underwent upfront pancreaticoduodenectomy and 119 who received neoadjuvant chemotherapy with gemcitabine and S-1 before pancreaticoduodenectomy were evaluated. Preoperative nutritional assessments (serum albumin, controlling nutritional status score, and prognostic nutritional index) showed no significant differences between groups, either at the initial consultation or immediately before surgery. No significant differences were observed in postoperative outcomes, including blood loss, operation time, and morbidity. The neoadjuvant chemotherapy with gemcitabine and S-1 group had a significantly greater rate of negative tumor margins (R0 resection rate 86% vs 74%, P = .018), and improved overall survival (hazard ratio, 0.41; 95% confidence interval, 0.25-0.67, P < .001) compared with the upfront pancreaticoduodenectomy group. CONCLUSIONS: Neoadjuvant chemotherapy with gemcitabine and S-1 does not adversely impact preoperative nutritional status and enhances the effectiveness of pancreaticoduodenectomy for resectable pancreatic ductal adenocarcinoma, leading to improved pathologically curative resection rates and overall survival.
引用
- Takamoto T, Nara S, Ban D, et al. Neoadjuvant gemcitabine and S-1 in pancreatic ductal adenocarcinoma: Effects on nutritional status and pancreaticoduodenectomy outcomes. Surgery. 2024. PMID: 39740600. doi:10.1016/j.surg.2024.109026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。